Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 6, 2011, Pages 499-506

  Lassailly, Guillaume ^a,b   Caiazzo, Robert ^c,d   Hollebecque, Antoine ^a,b   Buob, David ^e   Leteurtre, Emmanuelle ^e   Arnalsteen, Laurent ^c,d   Louvet, Alexandre ^a,b   Pigeyre, Marie ^f   Raverdy, Violeta ^d   Verkindt, Hélène ^d   Six, Marie France ^d   Eberle, Carole ^d   Patrice, Alexandre ^d   Dharancy, Sébastien ^a,b   Romon, Monique ^f   Pattou, François ^c,d   Mathurin, Philippe ^a,b  

^a UNIV LILLE   (France)

^b UNIVERSITÉ DE LILLE   (France)

^c INSERM   (France)

^d Service de Chirurgie Endocrinienne   (France)

^e D'Anatomie Pathologique   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Liver fibrosis; morbid obesity; noninvasive biomarkers; steatohepatitis

Indexed keywords

BIOLOGICAL MARKER;

ACTITEST; ADULT; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FATTY LIVER; FEMALE; FIBROTEST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; NASHTEST; NONALCOHOLIC FATTY LIVER; OBESITY; PREDICTIVE VALUE; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STEATOTEST;

EID: 79955606951     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283464111     Document Type: Article

References (28)

1. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355:763-778 (Pubitemid 44285582)
2. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346:987-990
3. Day CP, James OF. Steatohepatitis: A tale of two 'hits'? Gastroenterology 1998; 114:842-845 (Pubitemid 28160420)
4. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118:1117-1123 (Pubitemid 30346988)
5. Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Livingston EH, et al. Meta-analysis: Surgical treatment of obesity. Ann Intern Med 2005; 142:547-559
6. Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: A randomized controlled trial. JAMA 2008; 299:316-323 (Pubitemid 351159368)
7. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357:753-761 (Pubitemid 47295642)
8. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B,Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357:741-752 (Pubitemid 47295641)
9. Castillo J, Fabrega E, Escalante CF, Sanjuan JC, Herrera L, Hernanz F, et al. Liver transplantation in a case of steatohepatitis and subacute hepatic failure after biliopancreatic diversion for morbid obesity. Obes Surg 2001; 11:640-642 (Pubitemid 32907138)
10. Angulo P. NAFLD, obesity, and bariatric surgery. Gastroenterology 2006; 130:1848-1852 (Pubitemid 43668867)
11. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121:91-100 (Pubitemid 32591518)
12. Mathurin P, Gonzalez F, Kerdraon O, Leteurtre E, Arnalsteen L, Hollebecque A, et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 2006; 130:1617-1624 (Pubitemid 43668847)
13. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137:532-540
14. Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol 2008; 32:22-39
15. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6:6
16. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4:10
17. Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6:34
18. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467-2474 (Pubitemid 29420675)
19. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-1321 (Pubitemid 40770284)
20. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38:257-265 (Pubitemid 36286537)
21. Poynard T, Munteanu M, Ngo Y, Castera L, Halfon P, Ratziu V, et al. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Gastroenterol Clin Biol 2010; 34:388-396
22. Lambert J, Halfon P, Penaranda G, Bedossa P, Cacoub P, Carrat F. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: The area under the ROC curve revisited. Clin Chem 2008; 54:1372-1378
23. Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V, et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 2007; 53:1615-1622 (Pubitemid 47340057)
24. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495-500 (Pubitemid 32164902)
25. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001; 357:1069-1075 (Pubitemid 32322537)
26. The METAVIR cooperative group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20:15-20
27. Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, Bass NM. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44:874-880 (Pubitemid 46489551)
28. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128:1898-1906. (Pubitemid 40824701)